JP2021500409A - 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ - Google Patents

乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ Download PDF

Info

Publication number
JP2021500409A
JP2021500409A JP2020543474A JP2020543474A JP2021500409A JP 2021500409 A JP2021500409 A JP 2021500409A JP 2020543474 A JP2020543474 A JP 2020543474A JP 2020543474 A JP2020543474 A JP 2020543474A JP 2021500409 A JP2021500409 A JP 2021500409A
Authority
JP
Japan
Prior art keywords
peptide
amino acid
composition
acid sequence
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500409A5 (enExample
Inventor
ドリス ピーターキン，
ドリス ピーターキン，
マーク エー． コーエン，
マーク エー． コーエン，
Original Assignee
オンコペップ， インコーポレイテッド
オンコペップ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコペップ， インコーポレイテッド, オンコペップ， インコーポレイテッド filed Critical オンコペップ， インコーポレイテッド
Publication of JP2021500409A publication Critical patent/JP2021500409A/ja
Publication of JP2021500409A5 publication Critical patent/JP2021500409A5/ja
Priority to JP2023138078A priority Critical patent/JP2023155331A/ja
Priority to JP2025138218A priority patent/JP2025164866A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
JP2020543474A 2017-10-24 2018-10-23 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ Pending JP2021500409A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023138078A JP2023155331A (ja) 2017-10-24 2023-08-28 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ
JP2025138218A JP2025164866A (ja) 2017-10-24 2025-08-21 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762576404P 2017-10-24 2017-10-24
US62/576,404 2017-10-24
PCT/US2018/057039 WO2019083962A1 (en) 2017-10-24 2018-10-23 PEPTIDE AND PEMBROLIZUMAB VACCINES FOR THE TREATMENT OF BREAST CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023138078A Division JP2023155331A (ja) 2017-10-24 2023-08-28 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ

Publications (2)

Publication Number Publication Date
JP2021500409A true JP2021500409A (ja) 2021-01-07
JP2021500409A5 JP2021500409A5 (enExample) 2021-12-09

Family

ID=64650461

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543474A Pending JP2021500409A (ja) 2017-10-24 2018-10-23 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ
JP2023138078A Pending JP2023155331A (ja) 2017-10-24 2023-08-28 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ
JP2025138218A Pending JP2025164866A (ja) 2017-10-24 2025-08-21 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023138078A Pending JP2023155331A (ja) 2017-10-24 2023-08-28 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ
JP2025138218A Pending JP2025164866A (ja) 2017-10-24 2025-08-21 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ

Country Status (7)

Country Link
US (2) US12059463B2 (enExample)
EP (1) EP3700575A1 (enExample)
JP (3) JP2021500409A (enExample)
CN (1) CN111465411A (enExample)
AU (2) AU2018353984A1 (enExample)
CA (1) CA3079422A1 (enExample)
WO (1) WO2019083962A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102256001B1 (ko) * 2019-07-02 2021-05-26 주식회사 엔에이백신연구소 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
AU2020299074B2 (en) 2019-07-02 2024-02-22 Na Vaccine Institute Novel ribonucleic acid and pharmaceutical composition based on the same
EP4149483A4 (en) * 2020-05-15 2024-09-11 Fred Hutchinson Cancer Center COMPOSITIONS AND METHODS FOR IMPROVING CANCER IMMUNOTHERAPY
CN114231628A (zh) * 2021-12-03 2022-03-25 无锡臻和生物科技有限公司 预测胃肠肿瘤免疫检查点抑制剂疗效的标志物组合及其应用
WO2025101688A1 (en) * 2023-11-08 2025-05-15 Mary Hitchcock Memorial Hospital For Itself And On Behalf Of Dartmouth-Hitchcock Clinic (Collectively Doing Business As Dartmouth-Hitchcock) Combination therapy using tetrathiomolybdate

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1359937A4 (en) 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
ES2402184T5 (es) 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos
CA2726804C (en) * 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
JP6374392B2 (ja) * 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"NCT02826434", CRINICAITRIALS.GOV., vol. Version 5, JPN6022040823, 28 September 2017 (2017-09-28), ISSN: 0005209388 *
"Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or r", JOURNAL OF CLINICAL ONCOLOGY, vol. Volume 34, Issue 15_suppl, JPN6022040827, 2016, ISSN: 0005209391 *
BLOOD, vol. 124, no. 21, JPN6022040825, 2014, pages 4737, ISSN: 0005209389 *
LEUKEMIA (AUTHOR MANUSCRIPT), vol. 29, no. 1, JPN6022040826, 2015, pages 218 - 229, ISSN: 0005209390 *

Also Published As

Publication number Publication date
AU2018353984A1 (en) 2020-05-07
AU2024259780A1 (en) 2024-11-28
WO2019083962A1 (en) 2019-05-02
US12059463B2 (en) 2024-08-13
CA3079422A1 (en) 2019-05-02
JP2025164866A (ja) 2025-10-30
US20250018031A1 (en) 2025-01-16
CN111465411A (zh) 2020-07-28
US20200276304A1 (en) 2020-09-03
JP2023155331A (ja) 2023-10-20
EP3700575A1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
JP7838929B2 (ja) Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
JP2025164866A (ja) 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ
JP2013502421A (ja) 癌治療のためのｃｄ４４融合タンパク質の使用方法
WO2016205551A2 (en) Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
KR20220131223A (ko) Dkk-1 억제제를 사용하여 암을 치료하는 방법
US20190209669A1 (en) Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) Peptide vaccines and durvalumab for treating multiple myeloma
WO2019083960A1 (en) PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
HK1215531B (en) The use of compositions of xbp1, cd138, and cs1 peptides for preparing medicament
WO2025006989A2 (en) Methods for detection and treatment of cancer
HK40029255B (en) Anti-cd47 agent-based ovarian cancer therapy
HK40022679A (en) Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231127

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231208